Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Roka Furadada S L currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single matter is assigned to 1 distinct examiner, KRINOS, EMILY LYNN. The prosecution is further localized within 1 distinct art unit. KRINOS, EMILY LYNN is identified as the busiest examiner, holding 1 pending office action.
Because the entire pending portfolio consists of 1 pending office action, the company's legal strategy is highly focused. The involvement of only 1 distinct examiner and 1 distinct art unit means there is no variability in examination style across the current workload. Practitioners should tailor their approach specifically to the preferences of KRINOS, EMILY LYNN. The data shows that this 1 distinct examiner has total oversight of the company's active matters in the Biotechnology & Pharmaceuticals sector. This concentration simplifies the prosecution landscape but increases the impact of a single examiner's perspective.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KRINOS, EMILY LYNN | 1 | — | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19099323 | COMPOSITION COMPRISING A PHOTOCHEMICAL ULTRAVIOLET ABSORBER PRECURSOR AND A COMPOUND FOR INCREASING THEIR PHOTOCHEMICAL CONVERSION RATE | KRINOS, EMILY LYNN | — |
| Art Unit | Apps |
|---|---|
| 1614 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19099323 | COMPOSITION COMPRISING A PHOTOCHEMICAL ULTRAVIOLET ABSORBER PRECURSOR AND A COMPOUND FOR INCREASING THEIR PHOTOCHEMICAL CONVERSION RATE | KRINOS, EMILY LYNN | 1614 | §103§112 | Non-Final OA | — | Pending | Jan 28, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRoka Furadada S L has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Emily Lynn Krinos has the most, with 1 of Roka Furadada S L's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
